Log in to your account:
Bristol-Myers Squibb (BMY) Announces EC Approval for its Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Ph+ ALL
February 11, 2019 7:00 AM
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Sprycel (dasatinib) in combination with chemotherapy ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acu
February 11, 2019 6:59 AM